本文選題：基礎胰島素 + 阿卡波糖　； 參考：《中國糖尿病雜志》2017年03期

【摘要】：目的系統(tǒng)評價基礎胰島素聯(lián)合阿卡波糖對比預混胰島素治療T2DM的有效性和安全性,為臨床治療提供循證參考。方法計算機檢索Medline、PubMed、Science Direct、Springer Link、相關期刊論文、萬方和維普數(shù)據(jù)庫從2000~2016年的文獻,收集基礎胰島素聯(lián)合阿卡波糖(試驗組)對比預混胰島素(對照組)治療T2DM的隨機對照試驗(RCT),提取資料并進行質(zhì)量評價后,采用RevMan 5.3和Stata 12.0統(tǒng)計軟件進行Meta分析。結(jié)果共納入21項RCTs,試驗組818例,對照組809例。Meta分析結(jié)果顯示,試驗組FPG[SMD(95%CI)=-0.26(-0.42~-0.10),總體效應檢驗:Z=3.14,P=0.002]、2hPG[SMD(95%CI)=-0.27(-0.47~-0.07),總體效應檢驗:Z=2.66,P=0.008]、BMI[SMD(95%CI)=-0.83(-1.45~-0.20),總體效應檢驗:Z=2.6,P=0.009]及低血糖發(fā)生率[OR(95%CI)=0.33(0.22~0.48),總體效應模型:Z=5.66,P0.00001]低于對照組,而兩組HbA_1c水平比較,差異無統(tǒng)計學意義[SMD(95%CI)=-0.20(-0.44~0.04),總體效應檢驗:Z=1.61,P=0.11]。結(jié)論基礎胰島素聯(lián)合阿卡波糖治療T2DM在降低患者FPG、餐后血糖、BMI及低血糖發(fā)生率方面均優(yōu)于預混胰島素。
[Abstract]:Objective to evaluate the efficacy and safety of basic insulin combined with acarbose in the treatment of T2DM. Methods A computer-based search of Medlinea PubMeden Science Direct Springer Link. Chinese Journal Full-text Database, Wanfang and Weipu databases from 2000 to 2016 was conducted. The basic insulin and acarbose (trial group) were collected and compared with premixed insulin (control group) in the randomized controlled trial of T2DM. After extracting the data and evaluating the quality, the Meta was analyzed by RevMan 5.3 and Stata 12.0. 緇撴灉鍏辯撼鍏，

本文編號：1939752